Peptide Research Library
A summary of current preclinical and clinical findings on commonly researched peptide compounds, sourced from PubMed and other published literature. For research reference only — not medical advice.
BPC-157
Most published evidence comes from animal studies in rats, mice, and dogs, focused on musculoskeletal healing — including tendon, ligament, and muscle repair — as well as gut and nerve protection. A 2019 review noted its potential for aiding recovery in hypovascular tissues like tendons and ligaments, though comprehensive human clinical trials remain limited.
TB-500 (Thymosin Beta-4)
Animal and cell-based studies suggest thymosin beta-4, the source protein behind TB-500, supports wound healing by promoting cell migration, new blood vessel formation, and collagen deposition. Research has also examined its role in activating enzymes involved in tissue remodeling. Evidence remains largely preclinical, with limited human trial data specific to TB-500 itself.
CJC-1295
A 2006 randomized, placebo-controlled Phase 1 trial found that a single dose of CJC-1295 with DAC produced sustained elevations in growth hormone and IGF-1 levels in healthy adults, lasting 9 to 11 days. To date, no completed Phase 2 or Phase 3 efficacy trials in humans have been conducted.
Ipamorelin
The original 1998 study characterizing ipamorelin found it to be a highly selective growth hormone secretagogue, increasing GH release without significantly raising cortisol or prolactin, even at doses 200 times higher than needed for effect. Later rat studies showed dose-dependent increases in bone growth rate and body weight.
GHK-Cu (Copper Peptide)
In a rat model of ischemic skin wounds, daily topical GHK-Cu reduced wound area by 64.5% by day 13, compared to 45.6% with vehicle alone and 28.2% untreated, alongside lower inflammatory markers. Human clinical evidence remains limited, with most data coming from animal and in vitro models of skin and tissue repair.
PT-141 (Bremelanotide)
Unlike most research peptides, bremelanotide has gone through full FDA review and was approved in 2019 as a treatment for hypoactive sexual desire disorder in premenopausal women. A 2006 placebo-controlled crossover trial found significantly more participants reported increased sexual desire after receiving the peptide compared to placebo.
Epitalon (AEDG)
Animal studies in mice and rats have examined this pineal-derived peptide’s effects on lifespan and aging markers. One long-term study found it increased survival among the longest-lived 10% of treated mice by 13% and extended maximum lifespan by 12% versus controls, while a separate study found it reduced tumor incidence in aging mice. Human trial data is limited to the parent extract rather than the synthetic peptide.